Insight Partners eyes $14M bet on pharma-safety AI firm Graph AI

The News

Graph AI, a startup building artificial intelligence for the pharmaceutical and biotech industries, is in talks to raise roughly $14 million (about ₹133 crore) in a Series A round, according to a report from Inc42. The round is being led by the US growth investor Insight Partners, with existing backer Bessemer Venture Partners also expected to participate.

The discussions are not yet closed, and the final figure could still move. If it lands, the raise would arrive less than a year after Graph AI was founded in 2024, and only around eight months after the company picked up a $3 million seed cheque led by Bessemer.

The startup is run by chief executive Raghav Parvataraju, alongside co-founders Vijay Ponukumati as chief technology officer, Mohan Konyala as chief product officer, and Ashutosh Bordekar as chief financial officer. Its flagship product, Graph Safety, is a software platform that automates adverse drug event monitoring, regulatory submissions and broader safety intelligence for drugmakers. The company says the product is already live with enterprise customers.

Why It Matters

Pharmacovigilance, the unglamorous discipline of tracking whether a medicine is hurting the people who take it, is one of the most labour-heavy corners of the drug business. Every suspected side effect has to be logged as an individual case safety report, triaged, and filed with regulators on tight deadlines. Graph Safety pitches itself as the layer that unifies case processing, aggregate reporting, signal detection and compliance in one place.

That Insight Partners is circling a company this young says something about where enterprise software money is flowing. Investors spent the last two years chasing horizontal AI copilots; the shift now is towards narrow, regulated verticals where a wrong output has real consequences and incumbents move slowly. Drug safety fits that profile. The last comparable wave came when compliance-tech startups drew serious capital in the 2021 fintech boom, betting that regulation, not novelty, was the durable moat.

Indian Angle

For India, this is closer to home than the investor names suggest. The country is the world's largest supplier of generic medicines by volume and a major destination for global clinical research, which means its pharma companies generate an enormous stream of safety data that must satisfy the CDSCO at home and the US FDA and EMA abroad. The Pharmacovigilance Programme of India already coordinates adverse-event reporting nationally, and much of that filing work is still manual.

That gap is precisely what a platform like Graph Safety targets, and it puts Graph AI in the same territory as a growing set of Indian life-sciences software firms competing to automate regulatory drudgery for exporters in Hyderabad, Ahmedabad and Bengaluru. For domestic drugmakers such as Sun Pharma, Dr Reddy's and Cipla, cheaper and faster safety reporting is not a nicety; it is a direct lever on the cost of maintaining approvals in dozens of markets.

There is a talent and capital dimension too. A US fund writing a Series A cheque into pharma-AI signals to Indian founders and engineers, many of whom already staff the country's deep pool of pharmacovigilance outsourcing shops, that this domain can attract Tier-1 venture money. Expect Indian investors and the IT-services players who run drug-safety back offices to move faster on their own tooling if Graph AI succeeds.

FAQ

How much is Graph AI raising?

Around $14 million (₹133 crore) in a Series A led by Insight Partners, with Bessemer Venture Partners expected to return. The talks are still ongoing and the amount could change before the round is finalised.

What does Graph AI actually do?

Its platform, Graph Safety, automates drug-safety work for pharma and biotech firms, including adverse event monitoring, individual case safety reports, signal detection and regulatory submissions, aiming to replace slow manual processes.

How does this compare to its last round?

Graph AI raised a $3 million seed round led by Bessemer roughly eight months earlier. A $14 million Series A so soon after would represent a steep step-up for a company founded only in 2024.

Why should Indian pharma care?

India is the world's largest generics supplier and produces vast volumes of drug-safety data for regulators like the CDSCO, US FDA and EMA. Automating that reporting directly cuts compliance costs for major Indian exporters.

Where can I read the original report?

The funding talks were first reported by Inc42, whose coverage is linked in the attribution below.

This story was reported by Inc42. Read the full original coverage at Inc42.